165 results
8-K
PRTA
Prothena Corporation plc
28 May 24
Entry into a Material Definitive Agreement
4:15pm
Entry into a Material Definitive Agreement.
On May 24, 2024, pursuant to the existing ongoing global neuroscience research and development collaboration
8-K
EX-99.1
PRTA
Prothena Corporation plc
8 May 24
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
4:09pm
disease. BMS-986446 is part of a Global Neuroscience Research and Development Collaboration with Bristol Myers Squibb.
Bristol Myers Squibb has … with an undisclosed target, is part of a Global Neuroscience Research and Development Collaboration with Bristol Myers Squibb.
Phase 1 clinical trial
S-3ASR
PRTA
Prothena Corporation plc
22 Feb 24
Automatic shelf registration
5:29pm
and funding research and development. See “Use of Proceeds ” on page SA-7 for a more complete description of the intended use of proceeds from this offering … research and development. Until we use the net proceeds to us from this offering, if any, we plan to invest them, and these investments may not yield
8-K
EX-99.1
bnvrc6
15 Feb 24
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
4:09pm
8-K
EX-99.1
misap
8 Jan 24
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs
8:35am
8-K
EX-99.1
cfuqv7rpzu8j32cba
2 Nov 23
Prothena Reports Third Quarter 2023 Financial Results and Business Highlights
4:09pm
8-K
EX-99.1
cwc531
3 Aug 23
Prothena Reports Second Quarter 2023 Financial Results and Business Highlights
4:10pm
8-K
m378g3 xn6fdffxg
10 Jul 23
Entry into a Material Definitive Agreement
4:11pm
8-K
EX-99.1
f7o4k
4 May 23
Prothena Reports First Quarter 2023 Financial Results and Business Highlights
4:08pm
424B5
ti8ccdaotl1
16 Dec 22
Prospectus supplement for primary offering
4:31pm
424B5
dy0a yhyrjk13ogwzr
13 Dec 22
Prospectus supplement for primary offering
4:48pm